Dr. Reddy’s Enters US OTC Space With Bufferin, Other Ducere Brands
This article was originally published in The Tan Sheet
Executive Summary
Indian generics giant Dr. Reddy’s has made its first foray into the $40bn branded US consumer health goods market, buying half a dozen over-the-counter (OTC) labels, including well-known names like painkiller Bufferin, from Ducere.
You may also be interested in...
OTC New Products Roundup: NACDS Expo
Lidocaine cream and patches, zinc oxide spray and sleep aids among OTCs unveiled at trade show in Boston.
OTC New Products Roundup: NACDS Expo
Lidocaine cream and patches, zinc oxide spray and sleep aids among OTCs unveiled at trade show in Boston.
Share Fillip As Indian Pharma Crests US Regulatory Hump
For the last few years, Indian generic companies have been making headlines for all the wrong reasons, rapped by the US Food and Drug Administration over problems ranging from fudged test results to poor-quality manufacturing standards. But lately, the firms have been enjoying a run of good regulatory tidings, giving a fillip to their share prices.